Dublin biopharma developing GH001, a treatment for depression and other psychiatric conditions.
| Date | Round | Amount |
|---|---|---|
| Apr 2021 | Series B Dublin biopharma GH Research raised a $125m Series B led by RA Capital and RTW Investments to advance trials of its depression drug GH001. | $125M |